TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 50
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 55
2.4 CURRENCY AND PRICING 55
2.5 DBMR TRIPOD DATA VALIDATION MODEL 56
2.6 MULTIVARIATE MODELLING 59
2.7 PRODUCT TYPE LIFELINE CURVE 59
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.9 DBMR MARKET POSITION GRID 61
2.10 VENDOR SHARE ANALYSIS 62
2.11 MARKET END COVERAGE GRID 63
2.12 SECONDARY SOURCES 64
2.13 ASSUMPTIONS 64
3 EXECUTIVE SUMMARY 65
4 PREMIUM INSIGHT 68
4.1 PESTEL'S MODEL 69
4.2 PORTER'S 5 FORCES 70
4.3 EPIDEMIOLOGY 71
4.4 BRAND ANALYSIS 72
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET 76
4.6 INDUSTRY INSIGHTS: 78
5 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY 79
5.1 ASIA-PACIFIC 79
5.1.1 REGULATORY SCENARIO IN AUSTRALIA- 79
5.1.2 REGULATORY SCENARIO IN JAPAN 79
5.1.3 REGULATORY SCENARIO IN CHINA 79
5.1.4 REGULATORY SCENARIO IN SINGAPORE- 80
6 MARKET OVERVIEW 82
6.1 DRIVERS 84
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA 84
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING 84
6.1.3 INCREASE IN THE GERIATRIC POPULATION 85
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS 85
6.2 RESTRAINTS 86
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST 86
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES 86
6.3 OPPORTUNITIES 87
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS 87
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS 87
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS 88
6.4 CHALLENGES 89
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES 89
6.4.2 LIMITATIONS OF RADIATION TESTS 89
7 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 90
7.1 OVERVIEW 91
7.2 REAGENTS & CONSUMABLES 94
7.2.1 KITS 95
7.2.1.1 DNA POLYMERASE KITS 95
7.2.1.2 PCR KITS 95
7.2.1.3 NUCLEIC ACID ISOLATION KITS 95
7.2.1.4 OTHERS 95
7.2.2 REAGENTS 96
7.2.2.1 ASSAYS 96
7.2.2.2 BUFFERS 96
7.2.2.3 PRIMERS 96
7.2.2.4 OTHERS 96
7.3 INSTRUMENTS 97
7.4 SERVICES 98
8 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 99
8.1 OVERVIEW 100
8.2 CONFIRMATORY TEST 103
8.2.1 IMAGING TESTS 104
8.2.1.1 PET SCAN/CT SCAN 104
8.2.1.2 CT SCAN 104
8.2.1.3 ULTRASOUND 104
8.2.1.4 MRI 105
8.2.1.5 X-RAY 105
8.2.2 BIOMARKER 105
8.2.2.1 DNA BIOMARKER 105
8.2.2.2 RNA BIOMARKER 105
8.2.2.3 PROTEIN BIOMARKER 105
8.2.3 BIOPSY 105
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM 106
9 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP 107
9.1 OVERVIEW 108
9.2 GERIATRICS 111
9.3 ADULT 112
9.4 PEDIATRIC 113
10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE 114
10.1 OVERVIEW 115
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA 118
10.3 CARCINOID TUMOR 119
10.4 GASTROINTESTINAL STROMAL TUMOR 120
10.5 GASTRIC LYMPHOMA 121
10.6 OTHERS 122
11 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE 123
11.1 OVERVIEW 124
11.2 STAGE I 127
11.2.1 STAGE IA 128
11.2.2 STAGE IB 128
11.3 STAGE II 128
11.3.1 STAGE IIA 129
11.3.2 STAGE IIB 129
11.4 STAGE III 129
11.4.1 STAGE IIIA 130
11.4.2 STAGE IIIB 131
11.4.3 STAGE IIIC 131
11.5 STAGE 0 131
12 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER 132
12.1 OVERVIEW 133
12.2 MALE 136
12.3 FEMALE 137
13 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE 138
13.1 OVERVIEW 139
13.2 STOOL 142
13.3 TISSUE 143
13.4 BLOOD 144
13.5 URINE 145
14 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER 146
14.1 OVERVIEW 147
14.2 HOSPITALS 150
14.3 DIAGNOSTIC LABORATORIES 151
14.4 CANCER RESEARCH INSTITUTES 152
14.5 ONCOLOGY SPECIALTY CLINICS 153
14.6 OTHERS 154
15 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 155
15.1 OVERVIEW 156
15.2 DIRECT TENDERS 159
15.3 RETAIL SALES 160
16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION 161
16.1 ASIA-PACIFIC 162
16.1.1 SOUTH KOREA 172
16.1.2 JAPAN 177
16.1.3 CHINA 182
16.1.4 AUSTRALIA 187
16.1.5 SINGAPORE 192
16.1.6 INDIA 197
16.1.7 THAILAND 202
16.1.8 MALAYSIA 207
16.1.9 INDONESIA 212
16.1.10 PHILIPPINES 217
16.1.11 REST OF ASIA-PACIFIC 222
17 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 223
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 223
18 SWOT ANALYSIS 224
19 COMPANY PROFILE 225
19.1 F. HOFFMANN-LA ROCHE LTD 225
19.1.1 COMPANY SNAPSHOT 225
19.1.2 REVENUE ANALYSIS 225
19.1.3 COMPANY SHARE ANALYSIS 226
19.1.4 PRODUCT PORTFOLIO 226
19.1.5 RECENT DEVELOPMENT 226
19.2 GENERAL ELECTRIC 227
19.2.1 COMPANY SNAPSHOT 227
19.2.2 REVENUE ANALYSIS 227
19.2.3 COMPANY SHARE ANALYSIS 228
19.2.4 PRODUCT PORTFOLIO 228
19.2.5 RECENT DEVELOPMENT 228
19.3 ABBOTT 229
19.3.1 COMPANY SNAPSHOT 229
19.3.2 REVENUE ANALYSIS 229
19.3.3 COMPANY SHARE ANALYSIS 230
19.3.4 PRODUCT PORTFOLIO 230
19.3.5 RECENT DEVELOPMENT 230
19.4 QIAGEN 231
19.4.1 COMPANY SNAPSHOT 231
19.4.2 REVENUE ANALYSIS 231
19.4.3 COMPANY SHARE ANALYSIS 232
19.4.4 PRODUCT PORTFOLIO 232
19.4.5 RECENT DEVELOPMENT 232
19.5 MYRIAD GENETICS, INC. 233
19.5.1 COMPANY SNAPSHOT 233
19.5.2 REVENUE ANALYSIS 233
19.5.3 COMPANY SHARE ANALYSIS 234
19.5.4 PRODUCT PORTFOLIO 234
19.5.5 RECENT DEVELOPMENT 234
19.6 ACON LABORATORIES, INC. 235
19.6.1 COMPANY SNAPSHOT 235
19.6.2 PRODUCT PORTFOLIO 235
19.6.3 RECENT DEVELOPMENT 235
19.7 ADVACARE PHARMA 236
19.7.1 COMPANY SNAPSHOT 236
19.7.2 PRODUCT PORTFOLIO 236
19.7.3 RECENT DEVELOPMENT 236
19.8 AGILENT TECHNOLOGIES, INC. 237
19.8.1 COMPANY SNAPSHOT 237
19.8.2 REVENUE ANALYSIS 237
19.8.3 PRODUCT PORTFOLIO 238
19.8.4 RECENT DEVELOPMENTS 238
19.9 BIOMRIEUX 239
19.9.1 COMPANY SNAPSHOT 239
19.9.2 REVENUE ANALYSIS 239
19.9.3 PRODUCT PORTFOLIO 240
19.9.4 RECENT DEVELOPMENT 240
19.10 BIOCEPT, INC. 241
19.10.1 COMPANY SNAPSHOT 241
19.10.2 REVENUE ANALYSIS 241
19.10.3 PRODUCT PORTFOLIO 242
19.10.4 RECENT DEVELOPMENT 242
19.11 BIOHIT OYJ 243
19.11.1 COMPANY SNAPSHOT 243
19.11.2 REVENUE ANALYSIS 243
19.11.3 PRODUCT PORTFOLIO 244
19.11.4 RECENT DEVELOPMENT 244
19.12 DIASORIN S.P.A 245
19.12.1 COMPANY SNAPSHOT 245
19.12.2 REVENUE ANALYSIS 245
19.12.3 PRODUCT PORTFOLIO 246
19.12.4 RECENT DEVELOPMENT 246
19.13 ENDOFOTONICS PTE LTD 247
19.13.1 COMPANY SNAPSHOT 247
19.13.2 PRODUCT PORTFOLIO 247
19.13.3 RECENT DEVELOPMENT 247
19.14 FOUNDATION MEDICINE, INC. 248
19.14.1 COMPANY SNAPSHOT 248
19.14.2 PRODUCT PORTFOLIO 248
19.14.3 RECENT DEVELOPMENTS 248
19.15 FUJIREBIO (AN H.U. GROUP COMPANY) 249
19.15.1 COMPANY SNAPSHOT 249
19.15.2 REVENUE ANALYSIS 249
19.15.3 PRODUCT PORTFOLIO 250
19.15.4 RECENT DEVELOPMENT 250
19.16 MIRXES PTE LTD. 251
19.16.1 COMPANY SNAPSHOT 251
19.16.2 PRODUCT PORTFOLIO 251
19.16.3 RECENT DEVELOPMENT 251
19.17 PARAGON GENOMICS, INC. 252
19.17.1 COMPANY SNAPSHOT 252
19.17.2 PRODUCT PORTFOLIO 252
19.17.3 RECENT DEVELOPMENTS 252
19.18 TECO DIAGNOSTICS 253
19.18.1 COMPANY SNAPSHOT 253
19.18.2 PRODUCT PORTFOLIO 253
19.18.3 RECENT DEVELOPMENT 253
19.19 THERMO FISHER SCIENTIFIC INC. 254
19.19.1 COMPANY SNAPSHOT 254
19.19.2 REVENUE ANALYSIS 254
19.19.3 PRODUCT PORTFOLIO 255
19.19.4 RECENT DEVELOPMENTS 255
19.20 VELA DIAGNOSTICS 256
19.20.1 COMPANY SNAPSHOT 256
19.20.2 PRODUCT PORTFOLIO 256
19.20.3 RECENT DEVELOPMENTS 256
20 QUESTIONNAIRE 257
21 RELATED REPORTS 262

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.